Compatibility and stability of palonosetron hydrochloride with four neuromuscular blocking agents during simulated Y-site administration

International Journal of Pharmaceutical Compounding

Volumn 12, Issue 2, 2008, Pages 156-160

  Craig Trusley, P ^a   Ben, Michel ^b   Kupiec, Thomas C ^b   Trissel, Lawrence A ^c  

^a RUTGERS UNIVERSITY   (United States)

^b Analytical Research Laboratories   (United States)

^c TriPharma Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISATRACURIUM; INFUSION FLUID; NEUROMUSCULAR BLOCKING AGENT; PALONOSETRON; ROCURONIUM; SUXAMETHONIUM; VECURONIUM;

ARTICLE; CHEMOTHERAPY INDUCED EMESIS; DRUG INDICATION; DRUG MIXTURE; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INJECTION; POSTOPERATIVE NAUSEA AND VOMITING; ROOM TEMPERATURE; TURBIDIMETRY;

EID: 52949150749     PISSN: 10924221     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Aloxi [palonosetron hydrochloride package insert]. Bloomington, MN: MGI PHARMA, Inc., January 2006.
2. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14(10): 1570-1577.
3. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderate CINV with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: Results of a phase III, single-dose trial vs dolasetron. Cancer 2003; 98(11): 2473-2482.
4. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17(9): 1441-1449.
5. Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl in 4 infusion solutions. Ann Pharmacother 2004; 38(10): 1608-1611.
6. Trissel LA, Zhang YP. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin, and oxaliplatin during simulated Y-site administration. J Oncol Pharm Pract 2004; 10(4): 191-195.
7. Trissel LA, Zhang Y. Palonosetron hydrochloride compatibility and stability with doxorubicin hydrochloride and epirubicin hydrochloride during simulated Y-site administration. Ann Pharmacother 2005; 39(2): 280-283.
8. Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. IJPC 2005; 9(3): 238-241.
9. Trissel LA, Xu QA. Physical and chemical compatibility of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration. IJPC 2005; 9(3): 235-237.
10. Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. IJPC 2005; 9(4): 320-322.
11. Xu QA, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with cyclophosphamide and ifosfamide during simulated Y-site administration. Am J Health Syst Pharm 2005; 62(19): 1998-2000.
12. Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and methylprednisolone sodium succinate during simulated Y-site administration. IJPC 2006; 10(3): 234-236.
13. Xu QA, Trissel LA. Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am J Health Syst Pharm 2004; 61(15): 1596-1598.
14. Trissel LA, Trusley C, Ben M et al. Physical and chemical stability of palonosetron hydrochloride with five narcotics during simulated Y-site administration. Am J Health Syst Pharm [In press].
15. Ben M, Trusley C, Kupiec TC et al. Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration. IJPC [In press].
16. Trusley C, Ben M, Kupiec TC et al. Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration. IJPC 2007; 11(1): 82-85.
17. Allen LV Jr, Levinson RS, Phisutsinthrop D. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm 1977; 34(9): 939-943.
18. Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992; 49(7): 1716-1719.
19. Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993; 50(11): 300-304.
20. Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993; 50(11): 2359-2363.
21. Palonosetron HCl IV Injection 0.05 mg/mL and 0.15 mg/mL end product test procedure. Minneapolis, MN: MGI PHARMA, Inc.; [Undated].
22. Xu QA, Zhang YP, Trissel LA et al. Stability of cisatracurium besylate in vials, syringes, and infusion admixtures. Am J Health Syst Pharm 1998; 55(10): 1037-1041.